Ryo Amagai

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

Kyohei Nakamura, M. NAKAYAMA, Mitsuko Kawano et al. · Proceedings of the National Academy of Sciences · 2013 · 64 citations · Full text

Cancer Immunosurveillance, Cell Signaling, Medicine +13

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Frontiers in Medicine · 2019 · 23 citations · Full text

Advanced Cutaneous Melanoma, Tumor Biology, Cancer Immunosurveillance +14

A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial

Taku Fujimura, Koji Yoshino, Hiroshi Kato et al. · British Journal of Dermatology · 2024 · 21 citations

Plasminogen activating inhibitor‐1 promotes angiogenesis in cutaneous angiosarcomas

Kentaro Ohuchi, Ryo Amagai, Tetsuya Ikawa et al. · Experimental Dermatology · 2022 · 17 citations

Poor Clinical Outcomes, Angiogenesis, Cutaneous Angiosarcoma +13

The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors

Ryo Amagai, Toshiya Takahashi, H. Terui et al. · International Journal of Molecular Sciences · 2023 · 17 citations · Full text

Innate Immune System, Immunology, Cell Death +18